Skip to main content

Table 2 Demographic and clinical features a

From: Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy

Characteristics (N=30) Data
Mean age (range), yr 46.9 (27 to 80)
Mean tumor size (range), cm 2.46 (0.8 to 5.1)
Female gender, n (%) 30 (100%)
Mean tumor follow-up duration (range) months 61.2 (0.5 to 600)
Histologyb (N =30), n (%)  
  DCIS 7 (23.3%)
  LCIS 5 (16.7%)
  IDC 16 (53.3%)
  ILC 4 (13.3%)
TNM stage (N =30), n (%)  
  TisN0M0 10 (33.3%)
  T1aN0M0 1 (3.3%)
  T1bN0M0 3 (10.0%)
  T1aN1M0 1 (3.3%)
  Unclear 15 (30%)
Operation method (N =30), n (%)  
  BCS 20 (66.7%)
  Mastectomy 9 (30.0%)
  No data 1 (3.3%)
Lymph node dissection (N =30), n (%)  
  Axillary clearance 8 (26.7%)
  Sentinel lymph node dissection 11 (36.7%)
  Not done 1 (3.3%)
  No data 10 (33.3%)
Lymph node (N =30), n (%)  
  Metastasis 5 (16.7%)
  Negative 16 (53.3%)
  No data 9 (30.0%)
Receptor status  
  ER + (n =16) 11 (68.8%)
  PR + (n =16) 10 (62.5%)
  HER2+ (n =10) 1 (10.0%)
Further management  
  Chemotherapy (n =10) 4 (40.0%)
  Hormone therapy (n =10) 6 (60.0%)
  Radiation therapy (n =11) 5 (45.5%)
Outcome  
  Average follow-up (range), months 21.9 (5 to 59)
  Recurrence (n =16) 1 (6.3%)
  Distant metastasisc (n =16) 1 (6.3%)
  1. aBCS, Breast-conserving surgery; DCIS, Ductal carcinoma in situ; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; LCIS, Lobular carcinoma in situ; PR, Progesterone receptor; TNM, Tumor, node, metastasis. bOne patient had both LCIS and IDC, and another had both DCIS and LCIS. cDistant metastasis was noted at cancer diagnosis.